5α-reductase inhibitors and the risk of grade reclassification for men with long-term follow-up on active surveillance for prostate cancer.

被引：0
|
作者：
Finelli, Antonio
Timilshina, Narhari
Komisarenko, Maria
Sowerby, Robert
Hamilton, Robert James
Zlotta, Alexandre
Fleshner, Neil Eric
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Univ Toronto, Brampton, ON, Canada
[3] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Toronto, ON, Canada
[5] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期
关键词：
D O I：
10.1200/jco.2016.34.2_suppl.92
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
92
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer
    Ginsburg, Kevin B.
    Auffenberg, Gregory B.
    Qi, Ji
    Powell, Isaac J.
    Linsell, Susan M.
    Montie, James E.
    Miller, David C.
    Cher, Michael L.
    EUROPEAN UROLOGY, 2018, 74 (06) : 704 - 707
  • [32] 5-ALPHA REDUCTASE INHIBITORS DIMINISH THE RATE OF PROGRESSION IN MEN WITH LOW RISK PROSTATE CANCER ON ACTIVE SURVEILLANCE
    Finelli, Antonio
    Trottier, Greg
    Lawrentschuk, Nathan
    Sowerby, Robert J.
    Zlotta, Alexandre R.
    Radomski, Lenny
    Timilshina, Narhari
    Evans, Andrew
    van der Kwast, Theodorus H.
    Toi, Ants
    Jewett, Micheal A. S.
    Trachtenberg, John
    Fleshner, Neil E.
    JOURNAL OF UROLOGY, 2011, 185 (04): : E715 - E715
  • [33] 5-alpha reductase inhibitors diminish the rate of progression in men with low risk prostate cancer on active surveillance
    Finelli, A.
    Trottier, G.
    Lawrentschuk, N.
    Sowerby, R. J.
    Zlotta, A. R.
    Radomski, L.
    Timilshina, N.
    Evans, A.
    Van der Kwast, T. H.
    Toi, A.
    Jewett, M. A. S.
    Trachtenberg, J.
    Fleshner, N. E.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E1092 - U273
  • [34] Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long-term follow-up study
    Madhav, K. C.
    Oral, Evrim
    Rung, Ariane L.
    Trapido, Edward J.
    Rozek, Laura S.
    Fontham, Elizabeth T. H.
    Bensen, Jeannette T.
    Farnan, Laura
    Steck, Susan E.
    Song, Lixin
    Mohler, James L.
    Peters, Edward S.
    PROSTATE, 2022, 82 (07): : 783 - 792
  • [35] EFFECTIVENESS OF PERMANENT PROSTATE BRACHYTHERAPY IN YOUNG MEN WITH LONG-TERM FOLLOW-UP
    Salem, N.
    Bladou, F.
    Boher, J. M.
    Gravis, G.
    Walz, J.
    Resbaut, M.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S401 - S401
  • [36] Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer
    Huang, Mitchell M.
    Macura, Katarzyna J.
    Landis, Patricia
    Epstein, Jonathan, I
    Gawande, Rakhee
    Carter, H. Ballentine
    Mamawala, Mufaddal
    UROLOGY, 2020, 138 : 84 - 90
  • [37] LONG TERM FOLLOW-UP OF A LARGE ACTIVE SURVEILLANCE COHORT
    Klotz, Laurence
    Vesprini, Danny
    Loblaw, Andrew
    JOURNAL OF UROLOGY, 2014, 191 (04): : E411 - E412
  • [38] Long-term follow-up of radical retropubic prostatectomy for prostate cancer
    Swanson, GP
    Riggs, MW
    Earle, JD
    Haddock, MG
    EUROPEAN UROLOGY, 2002, 42 (03) : 212 - 216
  • [39] Incidence of Reclassification in Patients Undergoing Active Surveillance for Favorable-Risk Prostate Cancer.
    Kim, J.
    Davis, J. W.
    Ward, J.
    Wang, X.
    Pettaway, C.
    Pisters, L.
    Matin, S.
    Kuban, D.
    Frank, S. J.
    Lee, A. K.
    Prokhorova, I. N.
    Brown, V. T.
    Logothetis, C. J.
    Troncoso, P.
    MODERN PATHOLOGY, 2011, 24 : 204A - 204A
  • [40] Should Follow-up Biopsies for Men on Active Surveillance for Prostate Cancer Be Restricted to Limited Templates?
    Wong, L. M.
    Trottier, G.
    Toi, A.
    Lawrentschuk, N.
    Van der Kwast, T. H.
    Zlotta, A.
    Kulkarni, G.
    Hamilton, R.
    Trachtenberg, J.
    Evans, A.
    Timilshina, N.
    Fleshner, N. E.
    Finelli, A.
    UROLOGY, 2013, 82 (02) : 405 - 409
12345